Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agomelatine Sublingual in MDD
NCT01110889Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2010
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of agomelatine in major depressive disorder (MDD), sponsored by Novartis. Started May 2010; status: completed.
02
Drugs
agomelatine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01110889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01110889.